Original Research Article I Volume 5 I Issue 3 I 2017
Comparison between biodegradable polymer drug eluting stents and durable polymer drug eluting stents on the outcome of percutaneous coronary intervention in patients of Acute Coronary Syndrome
Abd-Allah Y. Fawzy; Mahmoud M. Kenawi; Ahmed A. Muhammad; Ayman N. Moharam; Ibrahim M. Attia
Biolife; 2017, 5(3), pp 377-382
DOI:https://doi.org/10.5281/zenodo.7371213
Abstract:
Introduction: Patients with NSTEACS have a wide spectrum of risk of death and cardiac ischemic events. Biodegradable polymer-based DES have been established as a safe and effective alternative to durable polymer-based stent platforms as evidenced in several randomized clinical trials. Aim of the study: to assess of the role of biodegradable polymer DES in decreasing the incidence of major adverse cardiac events in comparison with durable polymer DES in patients with NSTEACS.
Keywords:
Non-ST segment elevation acute coronary syndrome, biodegradable polymer DES, major adverse cardiac events
References:
- Cayla G, Silvain J, Collet JP and Montalescot G. Updates and current recommendations for the management of patients with non-ST-elevation acute coronary syndromes: what it means for clinical practice. Am J Cardiol, 2015. 115(5 Suppl): p. 10A-22A.
- Htay T and Liu MW. Drug-eluting stent: a review and update. Vasc Health Risk Manag, 2005. 1(4): p. 263-76.
- Stettler C, Wandel S, Allemann S, et al. Outcomes associated with drug-eluting and bare-metal stents: a collaborative network meta-analysis. Lancet, 2007. 370(9591): p. 937-48.
- Kastrati, A., Mehilli J, Pache J, et al. Analysis of 14 trials comparing sirolimus-eluting stents with bare-metal stents. N Engl J Med, 2007. 356(10): p. 1030-9.
- Finn AV, Nakazawa G, Joner M, Kolodgie FD, Mont EK, Gold HK, and Virmani R. Vascular responses to drug eluting stents: importance of delayed healing. Arterioscler Thromb Vasc Biol, 2007. 27(7): p. 1500-10.
- Byrne RA, Joner M, and Kastrati A. Polymer coatings and delayed arterial healing following drug-eluting stent implantation. Minerva Cardioangiol, 2009. 57(5): p. 567-84.
- Mehilli J, Byrne RA, Wieczorek A, et al. Randomized trial of three rapamycin-eluting stents with different coating strategies for the reduction of coronary restenosis. Eur Heart J, 2008. 29(16): p. 1975-82.
- Windecker S, Serruys PW, Wandel S, et al. Biolimus-eluting stent with biodegradable polymer versus sirolimus-eluting stent with durable polymer for coronary revascularisation (LEADERS): a randomised non-inferiority trial. Lancet, 2008. 372(9644): p. 1163-73.
- Barlis P, Regar E, Serruys PW, et al. An optical coherence tomography study of a biodegradable vs. durable polymer-coated limus-eluting stent: a LEADERS trial sub-study. Eur Heart J, 2010. 31(2): p. 165-76.
- Sanborn TA, Tcheng JE, Anderson HV, et al. ACC/AHA/SCAI 2014 health policy statement on structured reporting for the cardiac catheterization laboratory: a report of the American College of Cardiology Clinical Quality Committee. Circulation, 2014. 129(24): p. 2578-609.
- Kolh P and Windecker S. ESC/EACTS myocardial revascularization guidelines 2014. Eur Heart J, 2014. 35(46): p. 3235-6.
- Pollack CV, Sites FD, Shofer FS, Sease KL, and Hollander JE. Application of the TIMI risk score for unstable angina and non-ST elevation acute coronary syndrome to an unselected emergency department chest pain population. Acad Emerg Med, 2006. 13(1): p. 13-8.
Article Dates:
Received: 4 July 2017; Accepted: 29 August 2017; Published: 5 September 2017
How To Cite:
Abd-Allah Y. Fawzy, Mahmoud M. Kenawi, Ahmed A. Muhammad, Ayman N. Moharam, & Ibrahim M. Attia. (2022). Comparison between biodegradable polymer drug eluting stents and durable polymer drug eluting stents on the outcome of percutaneous coronary intervention in patients of Acute Coronary Syndrome. Biolife, 5(3), 377–382. https://doi.org/10.5281/zenodo.7371213
